February 2018 Issue Table Of Contents

From The Editor

• How To Stop Biopharma’s Negative Reputation Tailspin

Feature Articles

• The Intriguing Origins Of A Gene Therapy Biopharma
• PolarityTE: Beyond Cells, To Whole Tissue

Capitol Perspectives

• Government's Absurd View Of The Healthcare System

Patient Perspectives

• When Treatment For A Rare Disease Is On The Horizon, Hope Rises — And So Does Doubt

CEO Corner

• What Drug Developers Can Learn From Silicon Valley

Companies To Watch

• Zavante

Industry Research

• 2018 NDAs: Living In The Wake Of 2017

Inside The Industry

• Can Private Money Stop The Slump In Global R&D Funding?
• How To Survive The Perilous Life Sciences Startup Climb
• 2018 Likely A Banner Year For IPOs
• Navigating The Turbulent Waters From Discovery To Clinical
• The Missed Opportunity Of Medical Affairs
• Deal Building From Testing The Water To Hitting The Market
• The Art Of Leadership
• Putting Patients First
• How To Keep Employed In A Changing Biotech Workplace

Industry Leader

• Is Your Lab Prepared For A Cybersecurity Attack?

Leadership Lessons

• How To Create & Sustain A Culture Of Accountability

Ask The Board

• What Are The Greatest Challenges Facing Our Industry, And What Are Companies And Our Industry Doing To Meet Such Challenges?
• Why Are 505(b)(2)s Gaining Increased Interest Among Midsize Biopharma Companies?
• In Your Role As A Biopharmaceutical Angel Investor, What Are Some Questions You Ask And Why?